NCT07310719Recruiting
A Comparative Study of Intraocular Pressure Control Using Selective Laser Trabeculoplasty and Latanoprost as Initial Treatments for Primary Open Angle Glaucoma and Ocular Hypertension in Lagos State University Teaching Hospital
Selective Laser Trabeculoplasty Versus Latanoprost as First Line Treatments for Primary Open-angle Glaucoma and Ocular Hypertension: A Comparative Analysis
Source: ClinicalTrials.gov · Last updated 30 Dec 2025
Brief summary (registry, in English)
The goal of this clinical trial is to compare the short-term efficacy and safety of selective laser trabeculoplasty (SLT) to 0.005% latanoprost eye drops in lowering intraocular pressure (IOP) as primary therapy in treatment-naïve patients diagnosed as early to moderate primary open-angle glaucoma(POAG) or ocular hypertension (OHT) in the Lagos State University Teaching Hospital, Ikeja. The main questions it aims to answer are: 1. Will Selective Laser Trabeculoplasty be an equally effective treatment option compared with 0.005% Latanoprost eyedrops in reducing Intraocular Pressure when used alone as first-line therapy in Nigerian patients with POAG and OHT? 2. Will Selective Laser Trabeculoplasty record a similar safety profile compared with 0.005% Latanoprost when used independently as a primary therapy? 3. How will the quality of life of patients who undergo Selective Laser Trabeculoplasty treatment compare with patients on 0.005% Latanoprost eyedrops? Participants will be randomized to one of the two intervention groups. Group A(latanoprost group) will use 0.005% latanoprost eye drops every night at 2100hours(9.00pm) west African Time for 3 months. intraocular pressures will be monitored at intervals for a period of 3 months. Group B(SLT group) will have Laser treatment administered as a one-off treatment. intraocular pressures will be monitored at intervals for a period of 3 months. A record of side effects will be documented at each follow up visit
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 138 (estimated)
- First submitted
- 9 Dec 2025
- Start date
- 15 Oct 2025
- Primary completion date
- Sept 2026
- Lead sponsor
- Lagos State Health Service Commission
- Diseases
- Glaucoma, High blood pressure
- NCT number
- NCT07310719
What you commit to
- Study type: Interventional
- Planned participants: 138
- From 15 Oct 2025 to the primary completion date, Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- A prior medical, surgical, or laser treatment for glaucoma
- Patients who have undergone previous ocular surgeries (cataract surgery, trabeculectomy).
Other illness
- Patients with media opacity, such as cataracts, vitreous haze, or vitreous hemorrhage that prevents examination of the posterior segment.
- Patients with a history of ocular trauma or uveitis
Other
- Patients diagnosed with primary congenital glaucoma or secondary glaucoma
- Advanced glaucoma (CDR greater than 0.8, visual field analysis MD more than -12dB and DDLS stage 8 and above)
- Patients with cloudy cornea or corneal opacity that would impair the view of the anterior chamber angles, fundus, or give false IOP readings
- Pregnant and lactating women.
- \-
Who the study is looking for
- Patients aged 18years and above.
- Patients newly diagnosed as Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
- Patients with elevated IOP greater than 21mmHg (average of 3 measurements taken on 3 different clinic visits).
- Patients categorized as early or moderate glaucoma POAG (cup -disc ratio 0.5 to 0.7, visual field analysis MD - 6dB to -12dB and disc damage likelihood score (DDLS) 5 to 7) on funduscopy, Optical coherence tomography, and fundus photograph
- Patients who agree to participate in the study after informed consent.
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lagos State University teaching Hospital Eye Institute Coordinator of this site? Confirm its status | Ikeja | Nigeria | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.